HIVE's BUZZ HPC subsidiary secured a significant five-year AI cloud deal worth $350 million, adding $70 million in annual recurring revenue. OmniAb announced a global collaboration and license agreement with Eli Lilly, including an upfront payment and potential milestone payments up to $370 million. Freightos reported Q2 results that beat analyst estimates.
HIVE's BUZZ HPC subsidiary landed a substantial $350 million, five-year AI cloud deal with an investment-grade customer, immediately boosting its annual recurring revenue by $70 million to a total of $180 million. This is a significant positive catalyst for HIVE, demonstrating strong growth in its AI-focused operations and potentially re-rating its valuation. OmniAb (OABI) announced a global collaboration and license agreement with pharmaceutical giant Eli Lilly, which includes an upfront payment and up to $370 million in potential R&D and commercial milestone payments. This deal provides a substantial financial injection and validation for OmniAb's ion channel program, offering long-term growth prospects. Freightos (CRGO) reported Q2 adjusted EPS and sales that both exceeded analyst estimates, indicating better-than-expected operational performance. For traders, HIVE and OABI present immediate upside potential due to these major corporate developments, while CRGO's beat suggests a positive short-term reaction. The long-term implications for HIVE and OABI are particularly strong, given the strategic nature and financial scale of their respective announcements.